For instance, studies have found that anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibodies are a promising treatment for advanced gastric cancer (GC) patients, but the response rate remains limited, and it is necessary to develop new strategies to maximize the efficacy of immune checkpoint inhibitors (ICIs). This evidence concerns the gene PDCD1 and gastric cancer.